Merck India appoints Dhananjay Singh as MD of its Life Science unit

Over the years, Singh has taken on several leadership roles in commercial organisations such as Sigma-Aldrich and Merck India

pharma, medicine, drugs
Sanket Koul New Delhi
2 min read Last Updated : Apr 09 2024 | 2:41 PM IST

Don't want to miss the best from Business Standard?

Merck, a leading science and technology company, on Tuesday announced the appointment of Dhananjay Singh as the managing director of Merck Life Science in India.

Effective April 1, 2024, Singh has taken over from Sreenath N S, who is retiring after 36 years of service with Merck India.

“His (Singh’s) appointment will be in addition to his current position as Head of Science and Lab Solutions (Commercial), India, a position that he has held since 2022,” the company said.

In his role as the managing director, Singh will be responsible for driving the Life Science’s strategy in India, ensuring governance and compliance alongside other leaders from Merck’s businesses in India, according to the company statement.  

Over the years, Singh has taken on several leadership roles in commercial organisations such as Sigma-Aldrich and Merck India. 

Pratima Reddy, country speaker, Merck India said that Singh’s expertise in market dynamics and multi-stakeholder relationship management will further strengthen Merck Life Science’s position in the Indian market. 

After taking over the new responsibility, Singh said that Merck Life Science is committed to meeting customers’ demands with a strategic focus on ‘India for India and India for the Globe’. 

“With our strong partnerships with valued customers and our dedicated team, I am sure that the team will be able to drive our collective efforts toward achieving unparalleled success,” he said.  

“Together, we will be able to navigate the intricate landscape of the life sciences industry in India, steadfastly supporting government initiatives like “Make in India” to foster growth and innovation,” he added.  
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :MerckLife sciencePharma CompaniesCompanies

First Published: Apr 09 2024 | 2:31 PM IST

Next Story